CervoMed

What CervoMed does

CervoMed (NASDAQ: CRVO) is a clinical-stage biotechnology company developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits the protein kinase p38 alpha, which the company identifies as a key driver of synaptic dysfunction in early-stage neurodegenerative disease. The company's lead clinical program targets dementia with Lewy bodies (DLB), the second most common cause of neurodegenerative dementia, with no FDA- or EMA-approved treatments in the US or EU. CervoMed pursues a differentiated patient enrichment strategy using plasma ptau181 levels to identify DLB patients without Alzheimer's co-pathology — a subgroup representing up to 50% of the diagnosed DLB population in which synaptic dysfunction is considered primarily reversible. The lead asset is being developed across four indications: DLB (primary, Phase 3 planned for H2 2026), frontotemporal dementia (Phase 2, FDA Orphan Drug Designation), post-ischemic stroke recovery (Phase 2 Restore trial), and amyotrophic lateral sclerosis (Phase 2 via the UK EXPERTS-ALS platform).

The core technology rests on p38 alpha inhibition, supported by a new stable crystal form of neflamapimod (Phase 1 formulation study) that addressed prior bioavailability issues caused by unstable polymorphs. Clinical evidence includes the Phase 2a AscenD-LB and Phase 2b RewinD-LB trials (43 sites in US, UK, and Netherlands), with reported outcomes of a 3.5% increase in right basal forebrain volume (p=0.022 vs. placebo), 46% functional connectivity increase, and statistically significant improvements on CDR-SB (p<0.001 vs. old capsules; p=0.003 vs. placebo) and CGIC secondary endpoints. A USPTO notice of allowance issued in June 2026 extends composition/method IP protection into 2042, and the company holds FDA Fast Track Designation for DLB plus Orphan Drug Designation for FTD. Leadership includes alumni from Biogen, Vertex, Sanofi, Epizyme, and McKinsey with prior drug launch experience.

CervoMed is pre-revenue with no approved products or commercial distribution. Revenue is contingent on future FDA approval and commercialization of neflamapimod. To date, the company has funded operations through a $149.4M private placement (March 2024, RA Capital-led), a $21.3M NIH/NIA grant for the RewinD-LB trial, and two 2026 financings totaling $20.5M ($10.0M registered direct offering via H.C. Wainwright and a $10.5M private placement with institutional healthcare investors and insiders), with the cash runway extended into Q2 2027. The company is headquartered in Boston, Massachusetts (formerly EIP Pharma Inc., rebranded August 2023 following the merger that consolidated neflamapimod development under the current corporate entity).

Name

CervoMed

Legal name

CervoMed, Inc.

Website

https://cervomed.com

Company type

Public

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

CervoMed is a clinical-stage biotechnology company developing neflamapimod, an oral p38 alpha inhibitor, for neurodegenerative diseases including dementia with Lewy bodies, frontotemporal dementia, stroke recovery, and ALS. The publicly-traded company is preparing for Phase 3 trials in DLB.

Ownership category

akta.pro rank

Product category

Neurodegenerative Disease Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Cognitive & Behavioral Neurology (Dementia/Memory Disorders) (HLAKAIAH)

akta.pro secondary industries

Stroke & Vascular Neurology (HLAKAIAG), Clinical Trials Authorization & Oversight (GCP) (HLAJADAF)

Keywords

• Neurodegenerative disease therapeutics
• P38 alpha inhibitors
• Dementia with Lewy bodies
• Frontotemporal dementia treatment
• Clinical-stage biotechnology

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Neflamapimod commercialization: Pre-revenue clinical-stage biotechnology company. No approved products. Revenue expected upon FDA approval and commercialization of neflamapimod for dementia with Lewy bodies and potentially other indications including FTD and stroke recovery.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

CervoMed is a clinical-stage biotechnology company developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits the protein kinase p38 alpha. The lead candidate is being developed to reverse synaptic dysfunction in dementia with Lewy bodies (DLB), frontotemporal dementia (FTD), and post-stroke recovery. The company is pre-revenue with no approved products, advancing through Phase 2b and toward Phase 3 clinical trials.

Product overview

CervoMed is a clinical-stage biotechnology company developing a single lead drug candidate, neflamapimod, an oral small molecule p38 alpha inhibitor being developed for multiple neurodegenerative indications. The product pipeline includes neflamapimod for dementia with Lewy bodies (DLB), frontotemporal dementia (FTD), stroke recovery, and amyotrophic lateral sclerosis (ALS). The company operates clinical programs including the completed Phase 2b RewinD-LB trial and ongoing Phase 2a trials, with plans for Phase 3 in DLB and Phase 2a in FTD and stroke recovery.

Differentiator

Problem solved

Functional benefit

Products and services

• Neflamapimod Investigational orally administered small molecule brain penetrant that inhibits the protein kinase p38 alpha to reverse synaptic dysfunction in neurodegenerative diseases. Being developed for DLB, FTD, stroke recovery, and ALS.
• Neflamapimod for Frontotemporal Dementia Development of neflamapimod for frontotemporal dementia, targeting the nonfluent/agrammatic variant primary progressive aphasia patient population.
• Neflamapimod for Stroke Recovery Development of neflamapimod to improve recovery after moderately severe and severe ischemic stroke by enhancing neural plasticity.

Quantifiable outcome

• 3.5% increase in right basal forebrain volume (p=0.022 vs. placebo) at week 16
• +5 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• EXPERTS-ALS Platform (UK)coreStrategic or Co-development Partner · 18 February 2026Neflamapimod selected for inclusion in the UK's EXPERTS-ALS platform, a randomized multicenter Phase 2 trial designed to rapidly evaluate potential treatments for amyotrophic lateral sclerosis. The trial will evaluate approximately 35 ALS participants over 18-24 weeks, with first patient expected to be dosed by end of 2026. Trial costs are funded by UK government and leading motor neuron disease charities.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Alector: Clinical-stage biotech developing immuno-neurology approaches for FTD, Alzheimer's, and Parkinson's. Directly comparable as a neurodegenerative-focused company with an FTD program targeting a similar patient population as CervoMed's.
• AC Immune: Clinical-stage biotech developing therapeutics for neurodegenerative diseases with active programs in Alzheimer's, Parkinson's, and Down syndrome. Comparable as a CNS-focused company with multiple neurodegenerative programs and similar regulatory designation strategy.
• Cognition Therapeutics: Clinical-stage company focused on neurodegenerative diseases including DLB and Alzheimer's, with small-molecule SASP inhibitors. Highly comparable given the explicit DLB development focus and similar patient-enrichment strategies.
• Denali Therapeutics: Clinical-stage biotech developing therapeutics for neurodegenerative diseases including ALS, FTD, and Parkinson's. Comparable as a CNS-focused company pursuing multiple neurodegenerative indications with a novel mechanism of action.
• Anavex Life Sciences: Clinical-stage biotech developing small molecules for neurodegenerative and neurodevelopmental disorders, including Alzheimer's and Rett syndrome. Comparable as a small-cap CNS biotech with a single lead asset targeting synaptic/neuronal dysfunction.
• Prothena: Clinical-stage biotech developing protein-misfolding therapies for neurodegenerative diseases including DLB, Parkinson's, and Alzheimer's. Comparable as a single-asset-focused neuroscience company with active DLB clinical programs.

Broad incumbents

• Lundbeck: Global CNS-focused biopharma with established DLB and movement-disorder portfolio. Comparable as a large incumbent with active DLB commercial interests who could be a natural strategic acquirer or competitor.
• Biogen: Established neurology-focused biopharma with extensive neurodegenerative disease franchise. Relevant given Biogen's active DLB and Alzheimer's programs and because multiple CervoMed executives (CEO, CCO) are Biogen alumni with deep knowledge of competitive dynamics.
• Sage Therapeutics: Approved-product CNS biopharma developing therapies for CNS disorders. Comparable given CNS specialty focus and recent acquisition experience as a small-cap neurology company.

Emerging players

• Passage Bio: Clinical-stage biotech focused on rare CNS disorders including FTD and ALS. Comparable given overlapping FTD indication and clinical-stage status in neurodegenerative disease.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/Cervo_Med
• LinkedInlinkedin.com/company/cervomed

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CervoMed